AWKN

Awakn Life Sciences NEOE:AWKN Stock Report

Last Price

CA$0.17

Market Cap

CA$6.2m

7D

-16.7%

1Y

-43.5%

Updated

07 Dec, 2023

Data

Company Financials

AWKN Stock Overview

Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe.

AWKN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Awakn Life Sciences Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Awakn Life Sciences
Historical stock prices
Current Share PriceCA$0.17
52 Week HighCA$0.77
52 Week LowCA$0.055
Beta3.11
1 Month Change-7.89%
3 Month Change-37.50%
1 Year Change-43.55%
3 Year Changen/a
5 Year Changen/a
Change since IPO-91.97%

Recent News & Updates

Recent updates

Shareholder Returns

AWKNCA BiotechsCA Market
7D-16.7%-0.4%-1.8%
1Y-43.5%19.3%24.6%

Return vs Industry: AWKN underperformed the Canadian Biotechs industry which returned 19% over the past year.

Return vs Market: AWKN underperformed the Canadian Market which returned -1.2% over the past year.

Price Volatility

Is AWKN's price volatile compared to industry and market?
AWKN volatility
AWKN Average Weekly Movement46.2%
Biotechs Industry Average Movement12.3%
Market Average Movement8.8%
10% most volatile stocks in CA Market17.9%
10% least volatile stocks in CA Market3.5%

Stable Share Price: AWKN is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 46% a week.

Volatility Over Time: AWKN's weekly volatility has increased from 30% to 46% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a44Anthony Tennysonhttps://awaknlifesciences.com

Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.

Awakn Life Sciences Corp. Fundamentals Summary

How do Awakn Life Sciences's earnings and revenue compare to its market cap?
AWKN fundamental statistics
Market CapCA$6.17m
Earnings (TTM)-CA$7.53m
Revenue (TTM)CA$1.53m

4.4x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AWKN income statement (TTM)
RevenueCA$1.53m
Cost of RevenueCA$3.05m
Gross Profit-CA$1.52m
Other ExpensesCA$6.01m
Earnings-CA$7.53m

Last Reported Earnings

Jul 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.20
Gross Margin-99.09%
Net Profit Margin-491.55%
Debt/Equity Ratio0%

How did AWKN perform over the long term?

See historical performance and comparison